Vitamin B12 Deficiency: Signs, Tests and the Right Supplement Form

Vitamin B12 Deficiency: Signs, Tests, and Which Form of Supplement Works Best

Vitamin B12 deficiency is one of the most clinically significant nutritional deficiencies in the UK, yet it is routinely missed or misattributed — partly because its neurological symptoms can precede anaemia by months or years, and partly because standard serum B12 tests have limited sensitivity at borderline levels. Understanding who is at risk, what symptoms to look for, how to test meaningfully, and which supplement form to use can prevent serious and sometimes irreversible neurological consequences.

B12 Basics: A Unique Vitamin

Cobalamin (vitamin B12) is unique among vitamins in several respects. It is found almost exclusively in animal products — meat, fish, eggs, and dairy — with negligible amounts in plant foods (the small quantities in certain algae and fermented foods are largely inactive analogues). Vegans who do not supplement reliably will develop deficiency over months to years. This is a biochemical fact, not a dietary judgement.

B12 requires an elaborate absorption process. In the stomach, acid and pepsin release B12 from food proteins. The freed B12 binds to intrinsic factor (IF), a glycoprotein secreted by gastric parietal cells. The B12-IF complex then travels to the terminal ileum, where it is absorbed via cubilin receptors. This system is efficient but has multiple potential failure points.

Who Is at Risk?

Older adults: Gastric acid secretion declines with age. Around 10–30% of adults over 50 have atrophic gastritis (thinning of the gastric lining), which reduces acid and intrinsic factor production, impairing food-bound B12 absorption. Crystalline B12 in supplements is absorbed by passive diffusion and does not require intrinsic factor, making supplementation effective even when dietary absorption is compromised.

People taking PPIs or H2 blockers: Proton pump inhibitors (omeprazole, lansoprazole, etc.) profoundly suppress gastric acid. Studies show that long-term PPI use reduces serum B12. The UK's prescribing of PPIs is extremely high — estimated at over 50 million prescriptions per year — making iatrogenic B12 depletion a significant public health consideration.

People taking metformin: Metformin, the first-line diabetes medication, reduces B12 absorption via a mechanism involving calcium-dependent IF-B12 receptor activity in the ileum. UK guidance recommends periodic B12 monitoring in long-term metformin users.

Vegans and vegetarians: Without reliable supplementation or fortified foods, vegans will deplete B12 stores over time. The EPIC-Oxford cohort found that 52% of vegan participants had B12 deficiency.

People with pernicious anaemia: An autoimmune condition in which antibodies destroy parietal cells or intrinsic factor itself. Prevalence is approximately 0.1% of the population but higher in older women. This causes profound B12 deficiency that historically required intramuscular injections (which bypass the gut entirely), though high-dose oral supplementation is now established as an alternative.

Symptoms: Neurological Often Precedes Haematological

B12 is required for two major enzymatic pathways: the conversion of methylmalonyl-CoA to succinyl-CoA (essential for neurological health) and the regeneration of methionine from homocysteine (essential for methylation reactions including DNA synthesis).

Neurological symptoms (often preceding anaemia):

- Peripheral neuropathy — tingling, numbness, or burning in hands and feet - Subacute combined degeneration of the spinal cord — impaired proprioception and balance - Cognitive changes — memory impairment, confusion, depression - Visual disturbances

Haematological symptoms:

- Megaloblastic anaemia — large, immature red blood cells (macrocytosis on full blood count) - Fatigue, pallor, breathlessness

A critical clinical point: neurological damage from B12 deficiency can be irreversible if treatment is delayed. The neurological symptoms may appear before macrocytic anaemia develops, meaning a normal full blood count does not exclude significant B12 deficiency.

Testing: Standard Serum B12 and Its Limitations

A standard serum total B12 test measures all circulating B12 but does not distinguish between the active form (holotranscobalamin) and the inactive fraction. The reference ranges used by most UK NHS labs are relatively broad (typically 160–925 pmol/L), and many people with functional deficiency — who are depleted in tissues but not yet below this threshold — are told their results are "normal."

Functional B12 adequacy can be better assessed with:

- Holotranscobalamin (Active B12): Measures the metabolically active fraction. Levels below 35 pmol/L suggest deficiency. - Methylmalonic acid (MMA): Elevated MMA indicates functional B12 deficiency at the cellular level (MMA accumulates when the B12-dependent succinyl-CoA pathway is impaired). - Homocysteine: Elevated homocysteine indicates deficiency of B12 and/or folate.

If symptoms are present and serum B12 is in the lower-normal range, requesting active B12 or MMA provides considerably more useful clinical information.

Supplement Forms: Methylcobalamin vs Cyanocobalamin

Cyanocobalamin is a synthetic form of B12 used in most standard supplements and NHS prescriptions. It is stable, inexpensive, and effective — the body converts it to active forms (methylcobalamin and adenosylcobalamin). The "cyano" prefix refers to a cyanide ligand, which is released in trace amounts upon conversion; at supplemental doses, this is toxicologically irrelevant.

Methylcobalamin is the active form of B12 used in neurological tissue and in the methionine cycle. It does not require conversion and is the form some practitioners prefer for neurological indications. It is less stable and more expensive. Evidence from head-to-head comparative trials is limited, but methylcobalamin is widely used and preferred by many clinicians for those with neurological symptoms.

Both forms effectively raise serum B12 when dosed adequately.

Dosing: The Case for High Oral Doses

Standard dietary B12 is absorbed at approximately 1–2% efficiency via passive diffusion when the intrinsic factor mechanism is saturated (which occurs at relatively low doses, around 1–2mcg). At very high oral doses — 1,000mcg (1mg) or more — passive diffusion accounts for a sufficient absolute quantity (approximately 1–2% of 1,000mcg = 10–20mcg) to meet daily needs and replenish depleted stores.

This is the basis for high-dose oral supplementation (1,000mcg daily) as a clinically validated alternative to intramuscular injection, even in pernicious anaemia. A Cochrane review and subsequent RCTs have confirmed comparable outcomes between high-dose oral and intramuscular B12 for most patients.

Sublingual formulations (tablets dissolved under the tongue) bypass some first-pass processing, though the evidence that this produces meaningfully better absorption than swallowed high-dose tablets is inconsistent.

For most adults at risk of deficiency: 1,000mcg daily oral B12 (methylcobalamin or cyanocobalamin) is safe, effective, and appropriate.

Bottom Line

B12 deficiency is common, serious, and frequently missed because neurological symptoms precede anaemia and serum tests have limited sensitivity at borderline levels. Those at risk — older adults, PPI and metformin users, vegans — should supplement proactively with 1,000mcg daily. When deficiency is suspected despite a borderline standard test, active B12 and methylmalonic acid provide more useful clinical information. Methylcobalamin is the preferred form for neurological applications; cyanocobalamin is equally effective for prevention and general repletion.